Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Introduction Durvalumab has been shown to confer a survival benefit after definitive chemoradiotherapy in the patients with locally advanced non-small cell lung cancer, but no studies have attempted to identify risk factors for pneumonitis after durvalumab therapy. The purpose of this study was to i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Inoue, Hiroto, Ono, Akira, Kawabata, Takanori, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Yasui, Kazuaki, Ogawa, Hirofumi, Onoe, Tsuyoshi, Endo, Masahiro, Harada, Hideyuki, Takahashi, Toshiaki
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497668/
https://ncbi.nlm.nih.gov/pubmed/32128667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00917-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados